The COVID Vaccine Pause: A Case for Greater Patient Engagement

The COVID Vaccine Pause: A Case for Greater Patient Engagement

Despite initial concerns that the pause might fuel vaccine hesitancy and delay getting shots in arms of at-risk populations, the drug’s hiatus may have saved lives. In several early cases of J&J vaccine blood clotting, patients were treated with heparin, which is a normal treatment for blood clots; however, in these cases the heparin worsened the situation. The pause helped educate hospitals and health systems going forward on how to treat similar symptoms in those with the J&J dose.

To get in front of the situation, practices needed to quickly alert patients about the pause, address health concerns from patients who had already received the J&J shot, and help patients reschedule. It was only through rapid communication that providers could proactively resolve patient concerns, calm fears, and offer guidance.


Next Article

  • The COVID Vaccine Pause: A Case for Greater Patient Engagement

    Resilient Healthcare Facilities in a Post-COVID World

    Even before the pandemic, the industry was in the midst of transformation. “Now, care providers make money by keeping patients out of hospital beds, not in hospital beds, and administrators must adapt …

    Posted May 24, 2021

Did you find this useful?

Medigy Innovation Network

Connecting innovation decision makers to authoritative information, institutions, people and insights.

Medigy Logo

The latest News, Insights & Events

Medigy accurately delivers healthcare and technology information, news and insight from around the world.

The best products, services & solutions

Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.


© 2024 Netspective Media LLC. All Rights Reserved.

Built on Mar 28, 2024 at 3:00am